These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 33165773)

  • 21. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
    Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
    Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
    Groenendaal-van de Meent D; Kerbusch V; Barroso-Fernandez B; den Adel M; van Dijk J; Golor G; Schaddelee M
    Clin Ther; 2021 Jun; 43(6):1079-1091. PubMed ID: 33962762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure.
    Wolter K; Fritschka E
    Eur J Clin Pharmacol; 1993; 44 Suppl 1():S53-6. PubMed ID: 8387427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
    Shimasaki Y; Sakaki M; Itou M; Kobayashi T; Aso M; Kagawa T; Saiki T; Matsuno K; Sano Y; Shimizu K; Kuroda S; Koumura E
    Clin Drug Investig; 2018 Nov; 38(11):1041-1051. PubMed ID: 30194585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J; Henschel C; Chou J; Lin A; Del Balzo U
    Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
    Wang X; Tirucherai G; Marbury TC; Wang J; Chang M; Zhang D; Song Y; Pursley J; Boyd RA; Frost C
    J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Mass Balance Study of
    Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
    Grzeszczak W; Szczyra D; Śnit M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K; Li Z; Yu Y; Zhang X
    Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of switching treatment from high dose of darbepoetin to lower dose of roxadustat in Japanese hemodialysis patients.
    Kanda R; Kubo A; Seki T; Urita A; Sekiuchi M; Tomino Y
    Ther Apher Dial; 2022 Apr; 26(2):357-361. PubMed ID: 34333847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
    Shutov E; Sułowicz W; Esposito C; Tataradze A; Andric B; Reusch M; Valluri U; Dimkovic N
    Nephrol Dial Transplant; 2021 Aug; 36(9):1629-1639. PubMed ID: 33630072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with renal failure receiving hemodialysis and hemodiafiltration therapy
.
    Shi W; Tan X; Li Z; Zhang M; Huang B; Lu F; Jia J; Chen J; Zhong M
    Int J Clin Pharmacol Ther; 2019 Jun; 57(6):284-289. PubMed ID: 30935461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
    Henry DH; Glaspy J; Harrup R; Mittelman M; Zhou A; Carraway HE; Bradley C; Saha G; Modelska K; Bartels P; Leong R; Yu KP
    Am J Hematol; 2022 Feb; 97(2):174-184. PubMed ID: 34724251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.